Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20291881 | 0.99 | KCNH2 (0.53) | KCNH2RIPK1PIM1CCNT1CDK9 | |
| SCHEMBL17279189 | 0.93 | KCNH2 (0.53) | KCNH2RIPK1PIM1CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL20291928 | 0.92 | KCNH2 (0.53) | KCNH2RIPK1PIM1CCNT1CDK9 | |
| SCHEMBL17274102 | 0.77 | KCNH2 (0.54) | KCNH2RIPK1CCNT1CDK9 | |
| SCHEMBL15826116 | 0.76 | KCNH2 (0.49) | KCNH2PIM1FLT3PIM3PIM2 | |
| SCHEMBL20309801 | 0.74 | KCNH2 (0.51) | KCNH2PIM1FLT3PIM3PIM2 | |
| SCHEMBL20309858 | 0.73 | KCNH2 (0.47) | KCNH2PIM1FLT3PIM3PIM2 | |
| SCHEMBL8871896 | 0.73 | KCNH2 (0.50) | KCNH2PIM1FLT3PIM3PIM2 | |
| SCHEMBL8873534 | 0.71 | KCNH2 (0.46) | KCNH2PIM1FLT3LMNAMAPT | |
| SCHEMBL17279192 | 0.69 | KCNH2 (0.62) | KCNH2PIM1FLT3MAPTPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152249-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2017-06-01 | — | — | US | disclosed |
| US-9388192-B2 | Benzimidazole derivatives as Kinase Inhibitors | SELVITA S.A. (PL) | 2016-07-12 | — | — | US | disclosed |
| US-20150336967-A1 | Novel Benzimidazole Derivatives as Kinase Inhibitors | Ryvu Therapeutics S.A. (PL) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152249-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | PIM1, PIM3, PIM2 | KCNH2 2240/4885RIPK1 243/4885PIM1 1/4885 |
| US-20150336967-A1 | Novel Benzimidazole Derivatives as Kinase Inhibitors | PIM1, PIM3, PIM2 | KCNH2 2240/4885RIPK1 243/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.